Kolexia
Volet Julien Gastro-entérologie
Volet Julien
Gastro-entérologie
Polyclinique Reims - Bezannes
Bezannes, France
66 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs du pancréas Métastase tumorale Tumeurs colorectales Tumeurs du péritoine Tumeurs du foie Tumeurs du rectum Pneumopathies interstitielles Sarcopénie

Collaborateurs

Voir plus
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Brasseur Mathilde
Brasseur Mathilde
Hôpital Robert-Debré Reims, Reims, France
Desot Elise
Desot Elise
Institut Godinot, Reims, France
Lecomte Thierry
Lecomte Thierry
Hôpital Trousseau Chambray lès Tours, Chambray-lès-Tours, France

Industries

Voir plus
Sanofi
6 collaboration(s)
Dernière en 2021
Servier
5 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023
Amgen
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Les IPA (Infirmière de Pratique Avancée), Pourquoi et comment en pratique libérale ?
Youtube @ CREGG   01 janvier 2023
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Essai Clinique (Unicancer)   03 janvier 2022
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   30 avril 2020
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Cancer medicine   17 juillet 2019
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
The New England journal of medicine   11 janvier 2019
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
2018 ASCO Annual Meeting II   07 juin 2018
FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
2018 ASCO Annual Meeting I   01 juin 2018
A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
A phase IIb of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180).
2017 ASCO Annual Meeting I   30 mai 2017
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
The lancet. Gastroenterology & hepatology   28 février 2017